HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Non-invasive imaging to identify susceptibility for ventricular arrhythmias in ischaemic left ventricular dysfunction.

AbstractOBJECTIVE:
Non-invasive imaging of myocardial perfusion, sympathetic denervation and scar size contribute to enhanced risk prediction of ventricular arrhythmias (VA). Some of these imaging parameters, however, may be intertwined as they are based on similar pathophysiology. The aim of this study was to assess the predictive role of myocardial perfusion, sympathetic denervation and scar size on the inducibility of VA in patients with ischaemic cardiomyopathy in a head-to-head fashion.
METHODS:
52 patients with ischaemic heart disease and left ventricular ejection fraction (LVEF) ≤35%, referred for primary prevention implantable cardioverter-defibrillator (ICD) implantation, were included. Late gadolinium-enhanced cardiovascular MRI was performed to assess LV volumes, function and scar size. Using [(15)O]H2O and [(11)C]hydroxyephedrine positron emission tomography, both resting and hyperaemic myocardial blood flow (MBF), and sympathetic innervation were assessed. After ICD implantation, an electrophysiological study (EPS) was performed and was considered positive in case of sustained VA.
RESULTS:
Patients with a positive EPS (n=25) showed more severely impaired global hyperaemic MBF (p=0.003), larger sympathetic denervation size (p=0.048) and tended to have larger scar size (p=0.07) and perfusion defect size (p=0.06) compared with EPS-negative patients (n=27). No differences were observed in LV volumes, LVEF and innervation-perfusion mismatch size. Multivariable analysis revealed that impaired hyperaemic MBF was the single best independent predictor for VA inducibility (OR 0.78, 95% CI 0.65 to 0.94, p=0.007). A combination of risk markers did not yield incremental predictive value over hyperaemic MBF alone.
CONCLUSIONS:
Of all previously validated approaches to evaluate the arrhythmic substrate, global impaired hyperaemic MBF was the only independent predictor of VA inducibility. Moreover, a combined approach of different imaging variables did not have incremental value.
AuthorsMischa T Rijnierse, Cornelis P Allaart, Stefan de Haan, Hendrik J Harms, Marc C Huisman, Aernout M Beek, Adriaan A Lammertsma, Albert C van Rossum, Paul Knaapen
JournalHeart (British Cardiac Society) (Heart) Vol. 102 Issue 11 Pg. 832-40 (06 01 2016) ISSN: 1468-201X [Electronic] England
PMID26843532 (Publication Type: Comparative Study, Journal Article)
CopyrightPublished by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
Topics
  • Aged
  • Area Under Curve
  • Arrhythmias, Cardiac (diagnosis, etiology, prevention & control)
  • Cicatrix (diagnostic imaging, pathology)
  • Defibrillators, Implantable
  • Electric Countershock (instrumentation)
  • Electrophysiologic Techniques, Cardiac
  • Female
  • Heart (diagnostic imaging, innervation)
  • Humans
  • Logistic Models
  • Magnetic Resonance Imaging, Cine
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Myocardial Ischemia (complications, diagnostic imaging, pathology, physiopathology)
  • Myocardial Perfusion Imaging (methods)
  • Myocardium (pathology)
  • Odds Ratio
  • Positron Emission Tomography Computed Tomography
  • Predictive Value of Tests
  • Primary Prevention (instrumentation)
  • Prospective Studies
  • ROC Curve
  • Risk Factors
  • Sympathetic Nervous System (diagnostic imaging, physiopathology)
  • Treatment Outcome
  • Ventricular Dysfunction, Left (diagnostic imaging, etiology, physiopathology, therapy)
  • Ventricular Function, Left

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: